CRBP vs. CYRX, CMPS, OLMA, ARCT, AURA, ATAI, GLUE, SEPN, PVLA, and ATYR
Should you be buying Corbus Pharmaceuticals stock or one of its competitors? The main competitors of Corbus Pharmaceuticals include Cryoport (CYRX), COMPASS Pathways (CMPS), Olema Pharmaceuticals (OLMA), Arcturus Therapeutics (ARCT), Aura Biosciences (AURA), Atai Life Sciences (ATAI), Monte Rosa Therapeutics (GLUE), Septerna (SEPN), Palvella Therapeutics (PVLA), and Atyr PHARMA (ATYR). These companies are all part of the "pharmaceutical products" industry.
Corbus Pharmaceuticals vs.
Cryoport (NASDAQ:CYRX) and Corbus Pharmaceuticals (NASDAQ:CRBP) are both small-cap transportation companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, media sentiment, institutional ownership, community ranking, dividends, risk and profitability.
Cryoport has a beta of 1.81, meaning that its share price is 81% more volatile than the S&P 500. Comparatively, Corbus Pharmaceuticals has a beta of 3.12, meaning that its share price is 212% more volatile than the S&P 500.
In the previous week, Cryoport had 7 more articles in the media than Corbus Pharmaceuticals. MarketBeat recorded 10 mentions for Cryoport and 3 mentions for Corbus Pharmaceuticals. Cryoport's average media sentiment score of 0.85 beat Corbus Pharmaceuticals' score of 0.81 indicating that Cryoport is being referred to more favorably in the media.
Corbus Pharmaceuticals received 204 more outperform votes than Cryoport when rated by MarketBeat users. Likewise, 67.01% of users gave Corbus Pharmaceuticals an outperform vote while only 65.88% of users gave Cryoport an outperform vote.
Corbus Pharmaceuticals has lower revenue, but higher earnings than Cryoport. Cryoport is trading at a lower price-to-earnings ratio than Corbus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Cryoport presently has a consensus target price of $11.67, indicating a potential upside of 98.08%. Corbus Pharmaceuticals has a consensus target price of $59.13, indicating a potential upside of 608.08%. Given Corbus Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Corbus Pharmaceuticals is more favorable than Cryoport.
92.9% of Cryoport shares are held by institutional investors. Comparatively, 64.6% of Corbus Pharmaceuticals shares are held by institutional investors. 10.1% of Cryoport shares are held by company insiders. Comparatively, 4.0% of Corbus Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Corbus Pharmaceuticals has a net margin of 0.00% compared to Cryoport's net margin of -70.08%. Cryoport's return on equity of -13.35% beat Corbus Pharmaceuticals' return on equity.
Summary
Cryoport and Corbus Pharmaceuticals tied by winning 9 of the 18 factors compared between the two stocks.
Get Corbus Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRBP and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Corbus Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:CRBP) was last updated on 4/25/2025 by MarketBeat.com Staff
Buy CRBP Stock Free CRBP Stock Alerts